Rustin, representing the UK Medical Research Council (MRC) and European Organization for Research in Cancer Therapy (EORTC) Collaboration, reported the results of the OV05/55955 study that treatment of early-stage ovarian cancer patients in complete clinical remission based on elevated levels of CA 125 did not improve their survival compared to initiating treatment until they developed symptoms. The treatment of recurrence on the basis of elevated serum CA125 levels did not improve survival compared to initiating treatment until symptoms developed. Lymphoma 1, follicular lymphoma unique vaccine delayed recurrence: the United States of America University of Pennsylvania School of Medicine’s Schuster (Schuster) reported an eight-year randomized double-blind placebo-controlled phase III clinical study results: patient-specific autologous tumor-derived unique vaccine vaccination in patients with follicular lymphoma (FL), which can significantly prolong the relapse-free survival. 2. The SAKK35/98 study showed that in follicular lymphoma (FL), an additional 4 weeks of consolidation therapy given on top of 4 weeks of rituximab (once weekly for 4 weeks) resulted in a prolongation of the event-free survival (EFS) period at a median follow-up of 8.9 years (24 months vs. 13 months, P=0.0012), with 5- and 8-year EFS rates of 26% and 18%, respectively. 3, CORAL study showed that for CD20-positive diffuse large B-cell lymphoma (DLBCL), there was no significant difference in efficacy between the R-ICE regimen (rituximab + isocyclophosphamide + etoposide + carboplatin) and the R-DHAP regimen (rituximab + dexamethasone + cytarabine + cisplatin) (remission rate: 63.5% vs. 62.8%; 3-year EFS rate: 26% vs. 35%, P=0.6; 3-year OS rate: 47% vs. 51%, P=0.5). Breast cancer Treatment of triple-negative breast cancer new PARP inhibitor initial effect from Dallas, USA O’Shaughnessy (O’Shaughnessy) reported that patients with metastatic triple-negative breast cancer receiving poly(adenosine diphosphate ribose polymerase-1) (PARP1) inhibitor BSI-201 in combination with conventional chemotherapy (gemcitabine + carboplatin), the OS and progression-free survival (PFS) rate of patients with metastatic triple-negative breast cancer. progression survival (PFS) were superior to those of chemotherapy alone. Gastrointestinal tumors 1, ESPAC-3 study showed that as an adjuvant treatment for pancreatic cancer, there was no significant difference in the median OS period between gemcitabine and 5-fluorouracil (5-FU) combined with folinic acid (FA) treatment (23.6 months vs. 23 months), but the former was less toxic than the latter. 2, A large multicenter Italian study showed that the addition of oxaliplatin to neoadjuvant preoperative 5-FU + external pelvic irradiation radiotherapy did not improve pathological remission at the time of surgery in patients with locally advanced rectal cancer, and also led to an increase in toxicity. 3.A U.S. study showed that patients with uncomplicated newly diagnosed stage IV colorectal cancer did not require immediate surgery to remove their primary tumor, only 7% required emergency surgery to treat obstruction or perforation caused by the primary tumor, 4% required non-surgical interventions such as stenting or radiotherapy, and 89% did not require any direct symptomatic treatment to deal with their primary tumor. 4, ToGA study showed that for HER2 positive gastric cancer, compared with 5-FU or capecitabine + cisplatin chemotherapy alone, the median OS period of those who received trastuzumab + chemotherapy was significantly prolonged (13.8 months vs. 11.1 months, P=0.0048), and the objective remission rate was significantly higher (47.3% vs. 34.5%, P=0.0017). 5, early colon cancer adjuvant therapy bevacizumab does not improve 3-year DFS Wolmark, Allegheny General Hospital, reported the 3-year follow-up results of the phase III National Adjuvant Breast and Colon Surgery Program (NASBP) C-08 study: bevacizumab combined with chemotherapy for the adjuvant treatment of early colon cancer did not improve the rate of 3-year disease-free survival (DFS). Leukemia Bloomfield’s study showed that imatinib in combination with the Hyper-CVAD regimen resulted in 50% 5-year OS in patients with Ph+ ALL. When combined with SCT, the 6-year OS was 53%. Thus Ph+ALL is no longer an incurable leukemia Lung cancer 1. Biomarker analysis of the IPASS study confirmed that for those with EGFR mutations, gefitinib was superior to the carboplatin + paclitaxel (PC) chemotherapy group in terms of PFS (P<0.0001); objective remission rate (ORR) was also higher than that of the PC group (71.2% vs. 47.3%), whereas patients with EGFR wild-type who received gefi Gefitinib had less PFS and ORR than the chemotherapy group. 2, Pemetrexed maintenance therapy prolonged overall OS in patients with advanced NSCLC (13.4 months vs. 10.6 months, P=0.012) and in patients with non-squamous carcinoma (15.5 months vs. 10.3 months, P=0.002), but OS in the squamous carcinoma subgroup did not improve compared with that in the control group of the second-line treatment. 3, In the SATURN study, erlotinib maintenance therapy significantly prolonged the PFS period in patients with advanced NSCLC overall and in EGFR-positive patients (P<0.0001), and improved remission (12% versus 5%) and disease control (40.8% versus 27.4%, P<0.0001). 4, The ATLAS study demonstrated that the addition of erlotinib to bevacizumab significantly delayed disease progression in advanced NSCLC: the median progression-free survival (PFS) periods were 4.8 and 3.7 months in the two groups, respectively (P=0.0012), and neither group experienced any unanticipated adverse events. At this year's ASCO Annual Meeting, there were two major highlights of the presentations in the field of lung cancer. One was a biomarker-related study. The IPASS study in an Asian population confirmed the decisive impact of epidermal growth factor receptor (EGFR) mutation status on the first-line efficacy of gefitinib. It was concluded that this result could be extended to erlotinib and to populations outside of Asia, but that chemotherapy should remain the first-line treatment of choice for those with unknown mutation status. The second highlight is the maintenance therapy, this year, three studies in this field have achieved positive results, including pemetrexed maintenance therapy prolonged progression-free survival (PFS) and overall survival (OS), SATURN (with erlotinib maintenance) and ATLAS (with erlotinib + bevacizumab maintenance) two studies also significantly improved the PFS. the lung cancer community is gradually accepting the maintenance therapy as an effective and feasible treatment modality, but the lung cancer community is gradually accepting maintenance therapy as an effective and feasible treatment modality, but it is still the first line of chemotherapy for those with unknown mutation status. effective and feasible treatment modality, but the unanswered question from the three studies mentioned above is whether it is better to start maintenance therapy immediately after the end of first-line treatment than to leave the same drug until the disease has progressed? The congress commented that if the survival of the same drug is comparable between maintenance and second-line treatment, then a "therapeutic vacation" after first-line treatment may be a more reasonable option. While these recent data provide further evidence of the effectiveness of maintenance therapy, there are still many questions that need to be answered before the treatment paradigm can be changed. Most of the benefits of maintenance therapy have been in the area of PFS, and the congress review noted that improvements in PFS alone are of limited significance unless they are accompanied by control of tumor symptoms, reduction of complications, or improvement in quality of life. Until future studies provide a definitive answer, it cannot be said that maintenance therapy will become a routine modality, and three new studies have shown the promise of this modality if it can be demonstrated that it improves OS compared to second-line treatment with the same drug, or that it prolongs the PFS period while improving quality of life and symptoms. At the same time, it is necessary to explore the beneficiary population of maintenance therapy, and find a way out for maintenance therapy with individualized thinking. In terms of individualized treatment, the IPASS study by Asian scholars showed that EGFR mutation was significantly associated with PFS improvement and tumor remission, and the results support the first-line treatment of EGFR-TKI (gefitinib and erlotinib) for patients with EGFR mutation, which will change the first-line treatment pattern of advanced non-small cell lung cancer (NSCLC) with far-reaching significance. The subgroup analysis of pemetrexed maintenance therapy again confirmed that the drug could benefit patients with adenocarcinoma but failed to improve survival in patients with squamous carcinoma. It is evident that the future treatment of NSCLC will definitely form a new individualized treatment specification based on molecular markers and pathology.